ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
ProMIS reported positive blinded six-month interim safety and biomarker data from the Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer's disease, showing zero cases of ARIA-E across all 136 safety-evaluable participants and genotypes. A blinded pooled analysis demonstrated directionally consistent declines in biomarkers plasma pTau217 and CSF MTBR-tau243, supporting the thesis that selectively targeting toxic oligomers avoids plaque-related safety liabilities.
Key figures
- Drug Name
- PMN310
- Phase Of Trial
- Phase 1b
- Runway
- through 2027
- Net loss
- 11729656
- Private placement proceeds
- 70100000
- Cash and short term investments
- 53429280
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.